Publications of Michael Werner Sereda
All genres
Journal Article (48)
1.
Journal Article
24, pp. 47 - 60 (2021)
Microglia facilitate repair of demyelinated lesions via post-squalene sterol synthesis. Nature Neuroscience 2.
Journal Article
98 (10), pp. 1933 - 1952 (2020)
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats. Journal of Neuroscience Research 3.
Journal Article
27 (8), pp. 1390 - 1396 (2020)
Pregnancy outcome in Charcot–Marie–Tooth disease: results of the CMT‐NET cohort study in Germany. European Journal of Neurology 4.
Journal Article
9, e51406 (2020)
Proteome profile of peripheral myelin in healthy mice and in a neuropathy model. eLife 5.
Journal Article
39 (28), pp. 5606 - 5626 (2019)
Myelinating glia-specific deletion of Fbxo7 in mice triggers axonal degeneration in the central nervous system together with peripheral neuropathy. The Journal of Neuroscience 6.
Journal Article
10, 1467 (2019)
NRG1 type I dependent autoparacrine stimulation of Schwann cells in onion bulbs of peripheral neuropathies. Nature Communications 7.
Journal Article
14 (1), e0209752 (2019)
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A). PLoS One 8.
Journal Article
9, 3025 (2018)
Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nature Communications 9.
Journal Article
88 (11), pp. 941 - 952 (2017)
Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. Journal of Neurology, Neurosurgery & Psychiatry 10.
Journal Article
6, e23332 (2017)
Peroxisomal dysfunctions cause lysosomal storage and axonal Kv1 channel redistribution in peripheral neuropathy. eLife 11.
Journal Article
8, 17 (2017)
Rho kinase inhibition with Fasudil in SOD1(G93A) mouse model of Amyotrophic Lateral Sclerosis - symptomatic treatment potential after diesease onset. Frontiers in Pharmacology 12.
Journal Article
95 (11), pp. 145 - 157 (2016)
Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. Neurobiology of Disease 13.
Journal Article
19 (8), pp. 1050 - 1059 (2016)
Zeb2 is essential for Schwann cell differentiation, myelination and nerve repair. Nature Neuroscience 14.
Journal Article
18 (5), pp. 443 - 451 (2016)
The role of combined SNV and CNV burden in patients with distal symmetric polyneuropathy. Genetics in Medicine 15.
Journal Article
64 (1), pp. 155 - 174 (2016)
Proteolipid protein modulates preservation of peripheral axons and premature death when myelin protein zero is lacking. Glia 16.
Journal Article
2 (8), pp. 787 - 796 (2015)
Curcumin therapy in a Plp1 transgenic mouse model of Pelizaeus-Merzbacher disease. Annals of Clinical and Translational Neurology 17.
Journal Article
4, 53 (2015)
A brief review of recent Charcot-Marie-Tooth research and priorities. Faculty of 1000 Research 18.
Journal Article
9 (1), 201 (2014)
Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet Journal of Rare Diseases 19.
Journal Article
24 (11), pp. 1003 - 1017 (2014)
Selected items from the Charcot-Marie-Tooth (CMT) neuropathy score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. Neuromuscular Disorders 20.
Journal Article
34 (44), pp. 14506 - 14516 (2014)
Annexin A2 regulates TRPA1-dependent nociception. Journal of Neuroscience